BIOA advances Phase II oral NLRP3 inhibitor trials, pivotal data targeted
BIOA’s BGE-102 moved into two Phase II trials after Phase I, with results tied to biomarker readouts. The company is expanding into ophthalmology (including DME) and expects key data readouts by year-end and next year.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.